The Role of Deferiprone in Iron Chelation

N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219.

Authors

Robert C Hider¹, A Victor Hoffbrand¹

Affiliation

¹ From the Institute of Pharmaceutical Science, King's College London (R.C.H.), and the Department of Haematology, Royal Free Hospital (A.V.H.) - both in London.

PMID: 30485781
DOI: 10.1056/NEJMra1800219

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Anemia, Sickle Cell / therapy
Chelation Therapy
Deferiprone / adverse effects
Deferiprone / pharmacokinetics
Deferiprone / therapeutic use*
Deferoxamine / therapeutic use
Drug Therapy, Combination
Erythrocyte Transfusion / adverse effects
Humans
Iron Chelating Agents / adverse effects
Iron Chelating Agents / pharmacokinetics
Iron Chelating Agents / therapeutic use*
Iron Overload / drug therapy*
Iron Overload / etiology
Thalassemia / therapy

Substances

Iron Chelating Agents
Deferiprone
Deferoxamine